|1.||Staels, Bart: 21 articles (07/2011 - 12/2002)|
|2.||Staels, B: 12 articles (11/2005 - 01/2000)|
|3.||Fruchart, J C: 11 articles (01/2005 - 01/2000)|
|4.||Watts, Gerald F: 9 articles (01/2015 - 01/2004)|
|5.||Krysiak, Robert: 6 articles (01/2013 - 10/2004)|
|6.||Mikhailidis, D P: 6 articles (06/2012 - 01/2000)|
|7.||Fruchart, Jean-Charles: 6 articles (08/2007 - 12/2002)|
|8.||Wierzbicki, A S: 5 articles (04/2015 - 01/2001)|
|9.||Tziomalos, Konstantinos: 5 articles (01/2015 - 01/2006)|
|10.||Athyros, Vasilios G: 5 articles (01/2015 - 01/2006)|
04/21/1997 - "Fibrates have been shown to be most effective in treatment of the dyslipidemia in type III HLP. "
02/01/2015 - "We performed a meta-analysis of published data to compare the safety and efficacy of fibrates alone, compared to fibrate-statin combinations, in patients with dyslipidemia. "
01/01/2014 - "A meta-analysis of published data was conducted to compare the safety and efficacy of statins alone versus statins plus fibrates in patients with dyslipidemia. "
01/01/2014 - "Safety and efficacy of statin treatment alone and in combination with fibrates in patients with dyslipidemia: a meta-analysis."
08/01/2011 - "Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a meta-analysis."
05/01/2002 - "Conventional lipid lowering drugs such as statins and fibrates have the potency of reducing postprandial hyperlipidemia, but the fibrates seem to be more effective in this respect. "
03/01/2007 - "The study population (134,262 patients aged > or = 30 yrs) consisted of 55,118 patients who took statins and/or fibrates, 29,144 patients with hyperlipidemia not taking lipid-lowering agents, and 50,000 randomly selected patients without hyperlipidemia and without lipid-lowering treatment. "
09/01/2015 - "Hyperlipidemia, when present, was controlled by fibrates. "
01/01/2015 - "Fibrates can be administered in mixed hyperlipidemia, combined with statins in early CKD stages. "
01/01/2014 - "They were separated into three groups: control, untreated hyperlipidemia based on temporally screening, and hyperlipidemia with current anti-hyperlipidemic (statins and fibrates) treatment. "
11/01/2003 - "A combination of lifestyle modification, nutritional measures, and pharmacological intervention with statins or fibrates would achieve good results if the treatment of atherosclerosis were pursued vigorously. "
12/01/1994 - "It is concluded that the action of fibrates on these systems is such as to render the fibrates beneficial in atherosclerosis prevention."
08/01/2013 - "Fibrates decrease TG levels, increase HDL-C concentrations, and improve many other atherosclerosis-related variables. "
04/01/2010 - "Antihyperlipidemic drugs like statins and fibrates are widely used for prophylactic treatment in dyslipideamia and atherosclerosis. "
01/01/2008 - "Fibrates are widely prescribed in hyperlpidemic patients to prevent atherosclerosis. "
12/01/2001 - "Fibrates are particularly useful in the treatment of hypertriglyceridemia/low HDL. "
01/01/2014 - "Fibrates are the first-line treatment in patients with severe hypertriglyceridemia. "
01/01/2005 - "In patients with hypertriglyceridemia fibrates are effective, but there exist very few endpoint studies for this substance group. "
01/01/2001 - "Further clinical studies are necessary to investigate if fibric acids decrease cardiovascular mortality in type 2 diabetes and in primary prevention of hypertriglyceridemia and hypolipidemia."
01/01/2015 - "These data point to a possible role of hypertriglyceridemia in the development of CKD, though it remains to be demonstrated that diabetic individuals might benefit from triglyceride reduction with statins and eventually with combination therapy with fibrates. "
|5.||Cardiovascular Diseases (Cardiovascular Disease)
12/01/2002 - "Lipid lowering with statins and fibrates is effective in improving cardiovascular disease outcomes in diabetes, and their effectiveness is similar to that in the non-diabetic population. "
11/01/2007 - "The role of fibrates in the prevention of cardiovascular disease--a pooled meta-analysis of long-term randomized placebo-controlled clinical trials."
08/01/2006 - "Fibric acid derivatives in cardiovascular disease prevention: results from the large clinical trials."
02/01/2006 - "Clinical trials have indicated that the use of fibric acid derivatives confers a benefit against cardiovascular disease (CVD) in selected populations. "
01/01/2006 - "We will also analyze the major trial that evaluated fibrates for primary and secondary prevention of cardiovascular disease, the safety and efficacy profile of fibrate-statin combination treatment, and the current recommendations regarding the use of fibrates in clinical practice."
|1.||Niacin (Nicotinic Acid)
|6.||Peroxisome Proliferator-Activated Receptors (PPAR)
|9.||Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)
|1.||Drug Therapy (Chemotherapy)
|2.||Highly Active Antiretroviral Therapy (HAART)